European Pharmacopoeia Ph Eur Monograph Tablets 0478 Better < FRESH × Tutorial >
Advancing Pharmaceutical Quality: Why the Revised Ph. Eur. Monograph for Tablets (0478) is Better
: The Ph. Eur. Commission decided that dissolution or disintegration tests must be included in all specific monographs for immediate-release solid dosage forms to ensure better batch-to-batch consistency.
The provides the general quality standards for tablets intended for oral administration. It covers a variety of types, including uncoated, coated, gastro-resistant, and modified-release tablets. Key Quality Requirements
The monograph mandates strict tests for uniformity of content (2.9.40) or uniformity of mass (2.9.5).
Before a tablet can dissolve, it must break down into smaller particles. The disintegration test measures the time required for a batch of tablets to break up under specified conditions. For standard uncoated tablets, Ph. Eur. 0478 typically requires disintegration within 15 minutes in water at 37°C, while coated tablets may be allowed up to 60 minutes. Friability (2.9.7) and Resistance to Crushing (2.9.8) european pharmacopoeia ph eur monograph tablets 0478 better
To better understand monograph 0478, it is essential to consider the following:
Tablets must be robust enough to withstand manufacturing, packaging, and transport.
If a tablet is intended for division, the manufacturer must prove that the subdivided parts meet strict uniformity of mass tests (85% to 115% of the average mass of the subdivided parts), ensuring the patient receives a precise dose when breaking the tablet. B. Mandatory Dissolution/Disintegration Integration
This test is performed during product development to validate the tablet's design. The strict limits ensure that a patient splitting a tablet receives a dose that is highly accurate, regardless of which half they take. Advancing Pharmaceutical Quality: Why the Revised Ph
The monograph provides detailed criteria for coated, gastro-resistant, and modified-release tablets, ensuring that coatings are robust enough to withstand transit but dissolve at the correct location in the gut. 0478 vs. Other Standards: The "Better" Benchmark
The European Pharmacopoeia (Ph. Eur.) Monograph 0478 is the definitive regulatory standard for tablets intended for human use. Ensuring compliance with this monograph is not just a legal requirement for marketing authorized products in Europe; it is the foundation for achieving superior drug quality, safety, and therapeutic consistency.
user wants a long article about the European Pharmacopoeia monograph for tablets, specifically number 0478. They mention "better", which likely means they want information on how to improve compliance with the monograph or best practices.
establishes the legally binding quality standards for oral solid dosage forms marketed across 39 European countries. Maintained by the European Directorate for the Quality of Medicines & HealthCare (EDQM), this general dosage form monograph guarantees that tablets are manufactured with optimal uniformity, safety, and drug release characteristics. Implementing the rigorous criteria outlined in Monograph 0478 allows pharmaceutical companies to deliver better patient adherence, consistent in vivo bioequivalence, and seamless regulatory approval. Core Regulatory Scope of Monograph 0478 It covers a variety of types, including uncoated,
The revised Ph. Eur. Monograph 0478—notably updated in Supplement 9.3 and subsequent revisions, including 2020/2021 policy changes —offers significant improvements over older versions. These updates focus on clearer requirements for subdivision, improved functionality for dosage delivery, and more stringent dissolution requirements.
The monograph has seen significant revisions in recent supplements: Revised Ph. Eur. Chapter Tablets - ECA Academy
According to the monograph, tablets are . Traditionally, they are obtained by compressing uniform volumes of particles, but the monograph recognizes other manufacturing techniques such as extrusion, moulding, or freeze-drying (lyophilization).